Female Hair Loss
Different from men's, often treatable, and rarely talked about
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The 2016 Cochrane review by van Zuuren and colleagues pooled multiple RCTs and rated topical minoxidil as effective for female pattern hair loss on moderate-quality evidence (about 26 percent of minoxidil users reported moderate to marked regrowth versus 14 percent on placebo, plus an investigator-rated benefit and roughly 13 extra hairs per cm squared). A 2020 randomized trial (Ramos and colleagues) found low-dose oral minoxidil 1 mg non-inferior to topical 5 percent minoxidil. That places the mainstay treatment at grade 4, while the entry correctly separates reversible causes (telogen effluvium from thyroid disease, iron deficiency, or postpartum shedding) and keeps supplements and PRP as weaker claims.
Reference only. Not medical advice.
What can go wrong
Sudden or patchy hair loss, or loss with other symptoms, can signal a treatable medical condition and deserves evaluation rather than a supplement. Some causes are time-sensitive, so early assessment helps.
This is something to take to a clinician. The Atlas can tell you what is known about female hair loss in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Hair loss in women is common, tends to thin the hair broadly rather than create bald patches, and several causes are reversible once identified.
How it works
Female-pattern hair loss involves a genetic sensitivity of hair follicles to hormones, which gradually miniaturizes them. Other common causes are different: telogen effluvium is a temporary heavy shedding triggered by stress, illness, childbirth, or crash dieting, and deficiencies or thyroid disease can also thin hair.
What people get wrong
Often saidWomen's hair loss is just like men's.
ActuallyIt usually causes diffuse thinning rather than a receding line or bald spot, and the causes and treatments differ.
Often saidHair-growth gummies will regrow your hair.
ActuallyMost marketed supplements have weak or no evidence, while minoxidil and treating an underlying cause do have support.
Who profits, and who pushes back
Dermatology guidelines
Support minoxidil and treating underlying causes, and advise evaluation of sudden or patchy loss.
Hair-supplement brands
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Market gummies and formulas for regrowth, mostly without solid evidence.
Where the research comes from
Most of the published research on this comes from one place. 90% of it is from Global. Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| Global | 90% |
How we got here
Remedies for hair loss run through the historical record, from ancient Egyptian scalp ointments recorded in the Ebers papyrus to countless folk treatments. The modern clinical picture separates female pattern hair loss, a partly genetic and hormone-sensitive miniaturization of follicles graded on the Ludwig scale described in 1977, from reversible causes such as telogen effluvium, thyroid disease, and iron deficiency, and from alopecia areata, an autoimmune patchy loss. Topical minoxidil, first noticed to grow hair as a side effect of an oral blood-pressure drug, was approved for women in the 1990s, and cause-directed treatment plus low-dose oral minoxidil and anti-androgens developed across the 2000s to 2020s.
Chased with remedies since antiquity, women's hair loss is now understood as several distinct conditions, some genetic and hormonal and some reversible, which is what makes evaluation worthwhile.
- AntiquityHair-loss remedies recorded across cultures
- 20th centuryPattern loss distinguished from reversible causes
- 1990s-2020sMinoxidil and cause-directed treatment established
How it is understood
Women's hair loss usually shows as diffuse thinning, especially over the top of the scalp, rather than the receding hairline or bald crown more typical in men. Because hair is tied so closely to identity, the emotional impact is often heavy and under-acknowledged.
At a glance
- Typical pattern
- Diffuse thinning over the top
- Best-evidenced treatment
- Minoxidil
- Common reversible causes
- Iron deficiency, thyroid disease, stress shedding
- After childbirth
- Temporary shedding is common
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Female Hair Loss. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What people take it for. We have not catalogued the claims made for it.
Sources
Topical minoxidil is effective for female pattern hair loss on moderate-quality evidence; finasteride was no more effective than placebo (low quality)
Low-dose oral minoxidil 1 mg daily was non-inferior to topical 5 percent minoxidil over 24 weeks in women with female pattern hair loss
Topical minoxidil is the only FDA-approved treatment for female pattern hair loss; FPHL is a progressive miniaturization with shortened anagen and lengthened telogen; androgens' role is less clear than in men
Female Pattern Hair Loss (StatPearls / NCBI Bookshelf review)
Minoxidil is first-line for female pattern hair loss; low-dose oral minoxidil plus spironolactone can improve density; treatment continues at least six months and mostly slows progression
Telogen effluvium is a reactive diffuse shedding triggered by illness, surgery, postpartum hormonal change, thyroid disorders, iron deficiency, or stress; it does not cause bald patches and is usually self-limiting
Telogen effluvium differential includes androgenetic alopecia and alopecia areata; investigation covers iron and thyroid; postpartum shedding typically resolves within 6 to 12 months
Oral spironolactone 100 mg daily improved female pattern hair loss versus placebo in a small double-blind pilot RCT in premenopausal women
Low-dose oral minoxidil monotherapy in women showed acceptable safety with blood-pressure monitoring; hypertrichosis is the most common adverse effect
Safety and tolerability of low dose oral minoxidil monotherapy in female pattern hair loss (PMC)
Meta-analysis of platelet-rich plasma for female androgenetic alopecia suggests benefit but the evidence base is small and heterogeneous, so the strength of evidence is limited
Efficacy of oral finasteride in women with female pattern hair loss remains controversial with mixed results and no clear benefit in postmenopausal women
Efficacy of Finasteride in Female Pattern Hair Loss: A Meta-Analysis. Ann Dermatol 2021